文献速递细菌感染、耐药与抗菌药物医院感染防控

伴有菌血症的常见住院感染短疗程与长疗程疗效比较:多中心倾向加权队列研究

Effectiveness of Shorter Versus Longer Durations of Therapy for Common Inpatient Infections Associated With Bacteremia: A Multicenter, Propensity-Weighted Cohort Study.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该多中心回顾性队列研究纳入408例伴菌血症的单纯性肺炎、尿路感染或急性细菌性皮肤软组织感染住院患者,比较短疗程(5-9天,中位8天)与长疗程(10-15天,中位13天)的临床结局。倾向加权分析显示两组30天临床失败率无显著差异,但短疗程组重启抗生素和艰难梭菌感染风险更高,结论需前瞻性研究验证。

要点

  • 伴菌血症的肺炎、尿路感染或皮肤软组织感染短疗程不增加30天临床失败风险。

核心结论

  • 伴菌血症的肺炎、尿路感染或急性细菌性皮肤软组织感染短疗程(5-9天)与长疗程(10-15天)相比,30天临床失败复合终点风险无显著增加。
  • 但短疗程与重启抗生素及艰难梭菌感染风险升高相关,需前瞻性研究进一步评估。

研究设计与样本

  • 多中心回顾性队列研究,纳入408例伴菌血症的单纯性肺炎、尿路感染或急性细菌性皮肤软组织感染住院患者。
  • 短疗程组123例(中位8天),长疗程组285例(中位13天),采用倾向评分加权逻辑回归模型减少非随机分配偏倚。

关键数值与推荐

  • 短疗程定义为5-9天,长疗程定义为10-15天。
  • 主要结局为抗生素完成后30天内的临床失败复合终点(再住院、重启抗生素或全因死亡)。
  • 次要结局包括主要结局各组分、艰难梭菌感染及需改变治疗的抗生素相关不良反应。

临床怎么用

  • 对于伴菌血症的单纯性肺炎、尿路感染或急性细菌性皮肤软组织感染,短疗程(5-9天)未增加总体临床失败风险,但需警惕重启抗生素和艰难梭菌感染风险升高。
  • 临床决策应个体化权衡短疗程的获益与风险,目前证据不足以常规推荐短疗程替代长疗程。

局限性

  • 回顾性队列设计存在残余混杂可能,尽管使用了倾向评分加权。
  • 研究结论需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: National guidelines for pneumonia (PNA), urinary tract infection (UTI), and acute bacterial skin and skin structure infection (ABSSSI) do not address treatment duration for infections associated with bacteremia. We evaluated clinical outcomes of patients receiving shorter (5-9 days) versus longer (10-15 days) duration of antibiotics. METHODS: This was a multicenter retrospective cohort study of inpatients with uncomplicated PNA, UTI, or ABSSSI and associated bacteremia. The primary outcome was clinical failure, a composite of rehospitalization, reinitiation of antibiotics, or all-cause mortality within 30 days of antibiotic completion. Secondary outcomes included individual components of the primary outcome, Clostridioides difficile infection, and antibiotic-related adverse effects necessitating change in therapy. A propensity score-weighted logistic regression model was used to mitigate potential bias associated with nonrandom assignment of treatment duration. RESULTS: Of 408 patients included, 123 received a shorter treatment duration (median 8 days) and 285 received a longer duration (median 13 days). In the propensity-weighted analysis, the probability of the primary outcome was 13.5% in the shorter group and 11.1% in the longer group (average treatment effect, 2.4%; odds ratio [OR], 1.25; 95% confidence interval [CI], .65-2.40; P = .505). However, shorter courses were associated with higher probability of restarting antibiotics (OR, 1.62; 95% CI, 1.01-2.61; P = .046) and C. difficile infection (OR, 4.01; 95% CI, 2.21-7.59; P < .0001). CONCLUSIONS: Shorter courses of antibiotic treatment for PNA, UTI, and ABSSSI with bacteremia were not associated with increased overall risk of clinical failure; however, prospective studies are needed to further evaluate the effectiveness of shorter treatment durations.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hojat LS, Bessesen MT, Huang M, et al. Effectiveness of Shorter Versus Longer Durations of Therapy for Common Inpatient Infections Associated With Bacteremia: A Multicenter, Propensity-Weighted Cohort Study. Clin Infect Dis. 2020. PMID: 31858136. doi:10.1093/cid/ciz1197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。